Our Thinking

Is ‘Pharma Bro’ Martin Shkreli violating his lifetime industry ban? The FTC wants to know.

𝗧𝗵𝗶𝗻𝗸𝙁𝘼𝙎𝙏.  In what threatens to be yet another PR problem for pharma, we once again see “Pharma Bro” Martin Shkreli in the news.  Less than a year after being released from prison, and with a lifetime ban on “working in the pharmaceutical industry,” we see him founding a company, “Druglike,” that claims to be a “platform for democratizing the access, costs and rewards of early-stage drug discovery.” Not really a drug company, he says.  The FTC is not so sure.  
In any event, the man responsible for raising the price of Daraprim, used to treat AIDS and Cancer, from $17.50 to $750 per tablet during his time as CEO at Turing Pharmaceuticals, and as a result becoming “one of the most hated men in America,” who even inspired the Shkreli Awards, which call out the most dysfunctional players in healthcare,  is not likely to be a PR asset for the pharmaceutical industry.  Keep your eyes on this at: https://bit.ly/3IGk0US 

To view more ThinkFast posts: https://bit.ly/3Si5GFk


Contact us to learn how we can help your team to make better marketing decisions based on better market research.